Patents by Inventor Louis Cohen

Louis Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
    Patent number: 11919863
    Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 5, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Delmonte, Benjamin M. Cohen, Kenneth Joseph Fraunhoffer, Sergei Kolotuchin, Francisco Gonzalez-Bobes, Gregory Louis Beutner, Adam Joseph Freitag, Michael Scott Bultman, Yu Fan, Prantik Maity, Ian Scott Young, Hilary Plake Beck, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20230183286
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: August 16, 2022
    Publication date: June 15, 2023
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 11466048
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 11, 2022
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20200190132
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah Louise WILLIAMS, Jun YUAN, Frederic ZECRI
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 10676499
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 9, 2020
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Williams, Jun Yuan, Frederic Zecri
  • Human microbiota derived N-acyl amides for the treatment of human disease
    Publication number: 20200113950
    Abstract: The present invention provides compositions and methods for the modulation of G protein-coupled receptors (GPCRs).
    Type: Application
    Filed: June 29, 2018
    Publication date: April 16, 2020
    Inventors: Louis Cohen, Sean Brady
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 10112963
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20180002368
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: December 16, 2015
    Publication date: January 4, 2018
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah WILLIAMS, Jun YUAN, Frederic ZECRI
  • Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
    Patent number: 9789118
    Abstract: The present invention provides compounds of formula (IV); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (IV), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: October 17, 2017
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Gregory Raymond Bebernitz, Kevin Clairmont, Scott Louis Cohen, Robert Edson Damon, II, Robert Francis Day, Stephanie Kay Dodd, Christoph Gaul, Hatice Belgin Gulgeze Efthymiou, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Kai Lin, Justin Yik Ching Mao, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Su Liansheng
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20170015688
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • 2,3,5-trisubstituted thiophene compounds and uses thereof
    Patent number: 9498483
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Jiping Fu, Lei Shu, Rui Zheng
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9480693
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 1, 2016
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20150374726
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9163040
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: October 20, 2015
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • INSOLUBILIZATION OF WATER-SOLUBLE POLYARAMIDE BY CROSS-LINKING WITH POLYFUNCTIONAL AZIRIDINE
    Publication number: 20150266999
    Abstract: Compositions including a polyaramide cross-linked with a polyfunctional bridging group; compositions including a layer of a water-soluble polyaramide and a layer of a polyfunctional bridging group on the layer of water-soluble polyaramide; and methods of making and using those compositions are described. The compositions can be formed from water-soluble polyaramides and polyfunctional aziridine. The compositions can form components, films, and coatings. The compositions can be included in optical elements.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 24, 2015
    Inventors: Valeriy Kuzmin, David Taft, Louis Cohen
  • 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof
    Publication number: 20150224109
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Jiping FU, Lei SHU, Rui ZHENG
  • 2,3,5-trisubstituted thiophene compounds and uses thereof
    Patent number: 9040690
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: May 26, 2015
    Assignee: Novartis AG
    Inventors: David Barnes, Scott Louis Cohen, Jiping Fu, Lei Shu, Rui Zheng
  • Light Adjustable IOL With Diffraction Multifocal
    Publication number: 20140358226
    Abstract: A light adjustable diffraction multifocal intraocular lens (IOL), according to the present invention, is a mutifocal IOL whose optical power (prescription) may be adjusted by exposure to an energy source after implantation and subsequent wound healing. It makes use of a diffraction element to create the multifocal nature of the IOL which retains its structural integrity despite exposure to the power changing energy source.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventor: Allen Louis Cohen
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20140228323
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin Rigel
  • BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF
    Publication number: 20140171363
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Gregory Raymond BEBERNITZ, Kevin CLAIRMONT, Scott Louis COHEN, Robert Edson DAMON, II, Robert Francis DAY, Stephanie Kay DODD, Christoph GAUL, Hatice Belgin GULGEZE EFTHYMIOU, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Kai LIN, Justin Yik Ching MAO, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, SU Liansheng